Asia Pacific Anesthesia Drugs Market Outlook 2031
The Asia Pacific anesthesia drugs market size is was valued at USD XX Billion in 2022 and is likely reach to USD XX Billion by 2031, expanding at a CAGR of 5.9% during the forecast period, 2023–2031. The growth of the market is attributed to increasing awareness about the safe surgical procedures.
An anesthetic is a painkiller used during surgery. Many pieces of equipment, such as anesthetic vaporizers and nasal oxygen sets are specifically built for certain surgical procedures. Almost all surgical procedures today require anesthesia.
Anesthesia functions by preventing nerve signals from reaching the brain and keeping the patient awake. Procedures can be performed without the patient experiencing anything during this stage of induced sleep. Nerve signals are able to reach the brain once the anesthesia wears off.
Asia Pacific Anesthesia Drugs Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of chronic diseases and surgical procedure such as bypass surgery and pain control is anticipated to drive market growth.
- Decreasing efficacy of current drugs can hamper the market expansion.
- Favorable reimbursement policies can positively influence the market growth in the projected timeline.
- Expanding investment in R&D for developing novel and efficient drugs are creating ample opportunities for the anesthesia drugs market.
Scope of Asia Pacific Anesthesia Drugs Market Report
The report on the Asia Pacific anesthesia drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Anesthesia Drugs Market - Asia-Pacific Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Drug Types (General Anesthesia Drugs[Propofol, Sevoflurane, Isoflurane, Dexmedetomidine, Remifentanil, Desflurane, Midazolam, and Others], Local Anesthesia Drugs [Lidocaine, Ropivacaine, Chloroprocaine, Articaine, Benzocaine , Bupivacaine, and Others]), Route of Administrations (Injection, Inhalation, and Others), Applications (General Surgery, Plastic Surgery, Cosmetic Surgeries, Dental Surgeries, and Others)
|
|
Geographical scope
|
China, Japan, India, Australia, South Korea, and Rest of Asia Pacific
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Aspen Holdings; Baxter International; AbbVie Inc; Fresenius SE & Co. KGaA; and B. Braun Melsungen AG
|
Asia-Pacific Anesthesia Drugs Market Segment Insights
Local anesthesia drugs segment is expected to grow at a rapid pace
Based on drugs types, the market is divided into general anesthesia drugs, and local anesthesia drugs. The general anesthesia drugs segment is classified as propofol, sevoflurane, isoflurane, dexmedetomidine, remifentanil, desflurane, midazolam, and others.
The local anesthesia drugs segment is further categorized as lidocaine, ropivacaine, chloroprocaine, articaine, benzocaine, bupivacaine, and others. The local anesthesia drugs segment is expected to grow at a rapid pace during the forecast period owing to increasing number of accidents and surgeries.
Injection segment is projected to expand at a considerable CAGR
On the basis of route of administrations, the market is segregated into injection, inhalation, and others. The injection segment is projected to expand at a considerable CAGR during the forecast period due to technological advancements in drug delivery devices. Rising number of surgeries is propelling the segment growth.
Cosmetic surgeries segment is anticipated to account for a significant market share.
Based on applications, the market is divided into general surgery, plastic surgery, cosmetic surgeries, dental surgeries, and others. The cosmetic surgeries segment is estimated to account for a significant market share during the forecast period owing to rapid development of patient monitoring equipment and specially targeted medications.
Asia Pacific Anesthesia Drugs Market Regional Outlook
Japan is anticipated to constitute a key market share
In terms of geography, the Asia Pacific anesthesia drugs market is categorized China, Japan, India, Australia, South Korea, and Rest of Asia Pacific. Japan is expected to constitute a key share of the market during the projected period due to early technological adoption and highly specialized healthcare infrastructure. On the other hand, the market in India is expected to grow at a rapid pace during the forecast period.
Segments
Drug Types
- General Anesthesia Drugs
- Propofol
- Sevoflurane
- Isoflurane
- Dexmedetomidine
- Remifentanil
- Desflurane
- Midazolam
- Others
- Local Anesthesia Drugs
- Lidocaine
- Ropivacaine
- Chloroprocaine
- Articaine
- Benzocaine
- Bupivacaine
- Others
Route of Administrations
- Injection
- Inhalation
- Others
Applications
- General Surgery
- Plastic Surgery
- Cosmetic Surgeries
- Dental Surgeries
- Others
Geography
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Key Players
Competitive Landscape
Key players competing in the Asia Pacific anesthesia drugs market are Aspen Holdings; Baxter International; AbbVie Inc; Fresenius SE & Co. KGaA; and B. Braun Melsungen AG.
Request For Customization
Enquiry Before Buying
Speak With Analyst
